Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 09/23 05:35:07 pm
5170 GBp   +0.25%
09/23 ASTRAZENECA : Unique molecular atlas of pancreas produced
09/23 ASTRAZENECA : 23 September 2016 Innovative pancreatic research expan..
09/22 ASTRAZENECA : provides update on cediranib EU marketing authorisatio..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CEST

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
09/23 ASTRAZENECA : Unique molecular atlas of pancreas produced
09/23 ASTRAZENECA : 23 September 2016 Innovative pancreatic research expands treatment..
09/22 ASTRAZENECA : provides update on cediranib EU marketing authorisation applicatio..
09/22 ASTRAZENECA : Diabetes drug combo shows positive results in late-stage study
09/22 Synairgen Interim Loss Widens As It Continues Development Programmes
09/21 ASTRAZENECA : Patients at the core of partnership
09/21 ASTRAZENECA : 21 September 2016 AstraZeneca provides update on cediranib EU mark..
09/21 ASTRAZENECA : Withdraws European Marketing Application For Cediranib
09/21 Indian pharma firms in global alliance to fight drug resistance
09/20 ASTRAZENECA : 20 September 2016 Patients at the core of partnership
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/24 BIOTECH : What's Next For M&A?
09/23 Agenus' Immuno-Oncology Pipeline Has Promise
09/21 Allergan Sparks A Second Liver Disease Craze
09/21 ALLERGAN : Examining The Premiums Paid
09/19 The Puzzling Excuse For Novavax's Pivotal Failure
Advertisement
Financials ($)
Sales 2016 23 292 M
EBIT 2016 5 459 M
Net income 2016 2 589 M
Debt 2016 11 860 M
Yield 2016 4,21%
P/E ratio 2016 33,50
P/E ratio 2017 30,39
EV / Sales 2016 4,15x
EV / Sales 2017 4,31x
Capitalization 84 837 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 69,1 $
Spread / Average Target 3,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC11.99%85 496
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results